Could a fourth lead drug fi­nal­ly bring In­fin­i­ty an ap­proval?

Maybe fourth time’s the charm?

In­fin­i­ty Phar­ma­ceu­ti­cals, the thrice-failed on­col­o­gy biotech, an­nounced up­dat­ed da­ta Tues­day from its new lead drug in a pair of can­cers, show­ing that blad­der can­cer pa­tients who took its mol­e­cule in com­bi­na­tion with Bris­tol My­ers Squibb’s Op­di­vo lived near­ly twice as long as pa­tients who took Op­di­vo alone. And the biotech showed the mol­e­cule ap­peared to of­fer a mod­est ben­e­fit for pa­tients with triple-neg­a­tive breast can­cer.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER